Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples